INmune Bio Inc. announced dominant-negative inhibitor of soluble TNF, received correspondence from the FDA confirming that the full clinical hold on the Company?s AD clinical trial program has been lifted. The Phase II trial is on track to enroll the last patient mid-2024. Top line data is expected approximately six months after the last patient is enrolled.